Home > Insider Trading > Filing (0001104659-21-134623)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689375	Entrada Therapeutics Inc.	TRDA	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1425738	Redmile Group, Llc	One Letterman Drive Building D, Suite D3-300 San Francisco CA 94129	No	No	Yes	No
1650527	Jeremy Green	C/O Redmile Group, Llc One Letterman Drive, Building D #D3-300 San Francisco CA 94129	No	No	Yes	No
1838746	Redmile Biopharma Investments Iii, L.p.	C/O Redmile Group, Llc One Letterman Drive, Building D # D3-300 San Francisco CA 94129	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-11-02	954,420	$0.00	954,420	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-11-02	1,000,000	$20.00	1,954,420	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-11-02	954,420	$0.00	954,420	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.
These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Reflects number of shares owned as of November 2, 2021.